Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Thorax Education

Topic collections

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Citation Tools

Lung cancer

Original research

Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Kanabar SS, Tiwari A, Soran V, et al

Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review

Thorax 2022;77:1163-1174.